Clinigen Group plc (CLIN) Ordinary 0.1p
Share news, reports & tips
15 May 2019 12:43
(Sharecast News) - Aim\'s Clinigen Group is taking back control of two oncology drugs from US partner Cumberland Pharmaceuticals.
2 April 2019 10:57
(Sharecast News) - Clinigen now owns the global rights to Proleukin after having acquired the US rights to the treatment on Tuesday following US anti-trust clearance.
27 February 2019 10:23
(Sharecast News) - Specialty pharmaceuticals group Clinigen saw strong earnings and cash flow growth in the first half of its trading year following a period of transformative acquisitions.
20 February 2019 13:19
(Sharecast News) - Ocado: Peel Hunt downgrades to hold with a target price of 110p.
13 February 2019 12:50
(Sharecast News) - Workspace Group: Berenberg downgrades to hold with a target price of 900p.
13 February 2019 10:05
(Sharecast News) - Clinigen Group shares jumped on Wednesday after the company signed an agreement with Novartis to acquire the US rights to its Proleukin drug for up to $210m in cash.
5 February 2019 07:56
(Sharecast News) - AIM-listed pharmaceutical and services company Clinigen Group has appointed Nick Keher as its new chief financial officer with effect from 19 March.
15 January 2019 09:22
(Sharecast News) - Clinigen Group on Tuesday reported that, following a series of acquisitions, it expects to report a sharp rise in revenue and profit when it publishes its half-year results next month.
4 November 2018 17:14
(Sharecast News) - A round-up of share tips from the Sunday newspapers, including Clinigen in the Sunday Times, Mitie in the Sunday Telegraph and Warehouse REIT in the Mail on Sunday.
27 September 2018 12:14
(Sharecast News) - Thomas Cook Group: UBS upgrades to neutral with a target price of 60p.
27 September 2018 08:04
(Sharecast News) - Clinigen plans to raise £80m from investors to fund two new acquisitions following a "strong performance" from one of its previous additions in its last trading year.
25 July 2018 14:40
(Sharecast News) - Pharmaceutical and services company Clinigen has acquired the global rights to severe malignant osteoperosis treatment Imukin from Horizon Pharma for an undisclosed sum.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2019. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.